Progress continues toward a vaccine Pfizer and Moderna

 Meanwhile, progress continues toward a vaccine.

 Pfizer Inc. (PFE) and BioNTech SE (BNTX) on Wednesday said their vaccine candidate was 95% effective, according to a final analysis of clinical trial data. 

Moderna Inc. (MRNA) on Monday said its vaccine candidate was 94.5% effective. Both are expected to apply for U.S. regulatory authorization within days.